Stem Cell Transplantation for Newly Diagnosed M/M
ASCO 2022 on a Post Hoc Analysis of Sustained MRD Negativity From the GRIFFIN Trial: Dara + Len, Bortezomib, and Dex in Transplant-Eligible NDMM
By
ASCO 2022 Conference Coverage
FEATURING
Cesar Rodriguez
By
ASCO 2022 Conference Coverage
FEATURING
Cesar Rodriguez
Login to view comments.
Click here to Login
Stem Cell Transplantation for Newly Diagnosed M/M